New cancer drug SHR-4506 enters first human tests
NCT ID NCT07068932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new injection called SHR-4506 in 102 adults with advanced malignant tumors who have run out of standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow the disease. Participants must be in fairly good health and expected to live at least 12 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS OF ADULTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200127, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China